PUNE, India, April 4, 2018 /PRNewswire/ —
ReportsnReports.com adds the microfluidics market is projected to reach USD 27.91 billion by 2023 from estimated USD 10.06 billion in 2018, at a CAGR of 22.6%. Quick returns on investment coupled with the fast results and improved portability of the medical equipment embedded with microfluidics technology are the factors expected to drive the market during the forecast period. However, complex and time-consuming regulatory approvals process for the microfluidics technology into existing workflow is one of the factors restraining the growth of this market.
[…]
The key players in the global microfluidics market are Danaher (US), Thermo Fisher (US), PerkinElmer (US), Agilent (US), Bio-Rad (US), Becton, Dickinson and Company (US), Roche (Switzerland), Illumina (US), Fluidigm Microfluidics (US), and QIAGEN (Netherlands). Other key players include Dolomite Microfluidics (UK), GYROS PROTEIN TECHNOLOGIES AB (Sweden), Sphere Fluidics (UK), OPKO Health (US), Waters (US), thinXXS Microtechnology (Germany), Abaxis (US), BioMérieux (France), Abbott (US), Dolomite Microfluidics (UK), Microfluidic ChipShop (Germany), Elveflow (France), Cellix (Ireland), Micronit Microtechnologies (Netherlands), MicroLiquid (Spain), MiniFAB (Australia), uFluidix (Canada), Micralyne (US), and Fluigent (France).
Microfluidic devices are widely used to replicate the physical constraints bacteria experience in natural and…
Understanding how brain tumors interact with surrounding neural circuits is a significant challenge in neuro-oncology.…
Timely identification of infectious pathogens remains a major bottleneck in clinical care, particularly in conditions…
Early diagnosis of sickle cell disease remains a major challenge, particularly in low-resource settings where…
Understanding the interplay between surface chemistry, pore geometry, and flooding fluids remains a central challenge…
Soil hosts dense and diverse microbial communities that drive major ecological processes, yet the way…